NASDAQ:ICPT

Intercept Pharmaceuticals Stock Forecast, Price & News

$17.24

+0.37 (+2.19 %)

(As of 07/29/2021 04:00 PM ET)

Add

Compare

Today's Range

$17.24

▼

$18.50

50-Day Range

$15.46

▼

$22.06

52-Week Range

$13.88

▼

$55.59

Volume754,924 shs

Average Volume989,718 shs

Market Capitalization$571.71 million

P/E RatioN/A

Dividend YieldN/A

Beta1.56

30 days | 90 days | 365 days | Advanced Chart

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
July 29, 2021 | seekingalpha.com

Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Gap Up to $16.87
July 29, 2021 | americanbankingnews.com

Intercept Pharmaceuticals: Q2 Earnings Insights
July 29, 2021 | benzinga.com

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
July 29, 2021 | finance.yahoo.com

Earnings Outlook For Intercept Pharmaceuticals
July 28, 2021 | benzinga.com

Intercept Pharmaceuticals (ICPT) Set to Announce Quarterly Earnings on Thursday
July 22, 2021 | americanbankingnews.com

Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
July 19, 2021 | finance.yahoo.com

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
July 19, 2021 | finance.yahoo.com

Intercept Pharmaceuticals, Inc. Common Stock (ICPT)
July 17, 2021 | nasdaq.com

Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Gap Down to $17.22
July 15, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
Previous Symbol
CUSIP45845P10
CIK1270073
Webwww.interceptpharma.com
Phone646-747-1000
Employees498
Year FoundedN/A

Sales & Book Value

Annual Sales$312.69 million
Price / Sales1.83
Cash FlowN/A
Price / Cash FlowN/A
Book Value($5.05) per share
Price / Book-3.41

Profitability

EPS (Most Recent Fiscal Year)($8.34)
Net Income$-274,880,000.00
Net Margins-69.11%
Return on EquityN/A
Return on Assets-38.17%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares33,162,000
Market Cap$571.71 million
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.21 out of 5 stars

Medical Sector

111th out of 2,214 stocks

Pharmaceutical Preparations Industry

52nd out of 869 stocks

4.1 Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 6 buy ratings, 13 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $37.95, Intercept Pharmaceuticals has a forecasted upside of 120.1% from its current price of $17.24.
Amount of Analyst Coverage
Intercept Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.8 Community Rank

Outperform Votes
Intercept Pharmaceuticals has received 1,045 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intercept Pharmaceuticals has received 332 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intercept Pharmaceuticals has received 75.89% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote “Outperform” if you believe ICPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.90% of the stock of Intercept Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
73.88% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($4.63) to ($4.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

Is Intercept Pharmaceuticals a buy right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Intercept Pharmaceuticals?

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its earnings results on Thursday, July, 29th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.24) by $0.91.
View Intercept Pharmaceuticals' earnings history.

How has Intercept Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have decreased by 77.8% and is now trading at $17.24.
View which stocks have been most impacted by COVID-19.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, July, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $325 million-$340 million, compared to the consensus revenue estimate of $334.31 million.

What price target have analysts set for ICPT?

20 equities research analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $16.00 to $88.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $37.95 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:

Mr. Jerome B. Durso, Pres, CEO & Director (Age 53, Pay $853.17k)
Dr. Mark Pruzanski, Founder, Advisor & Director (Age 53, Pay $1.3M)
Mr. Andrew Saik, Chief Financial Officer (Age 52)
Mr. Rocco Venezia, Chief Accounting Officer & Treasurer
Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
Mr. Jared M. Freedberg, Gen. Counsel (Age 52)
Mr. David Ford, Chief HR Officer (Age 51)
Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical Officer (Age 58)
Ms. Linda M. Richardson, Exec. VP & Chief Commercial Officer (Age 57)
Mr. Bryan Ball, Chief Quality Officer (Age 51)

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

Who are some of Intercept Pharmaceuticals' key competitors?

Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ICPT's competitors.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $17.24.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of $571.71 million and generates $312.69 million in revenue each year. The biopharmaceutical company earns $-274,880,000.00 in net income (profit) each year or ($8.34) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

Intercept Pharmaceuticals employs 498 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

Where are Intercept Pharmaceuticals' headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here